3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
45
Neoplasm Metastasis
5
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Bulbo-Spinal Atrophy, X-Linked
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Salivary Gland Neoplasms
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Interventions
enzalutamide
3
darolutamide
2
abiraterone
2
pembrolizumab
1
bicalutamide
1
abemaciclib
1
Prednisolone
1
Goserelin
1
Docetaxel
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Bulbo-Spinal Atrophy, X-Linked
×
abiraterone
×
1 year
×
Clear all
NCT07190300
2026-06-03
TulmiSTAR-02
Novartis
Phase 1/2
Recruiting
181 enrolled
NCT06764485
2026-05-06
rechARge
Celgene
Phase 3
Recruiting
960 enrolled